Toll-like receptor 4 complex (TLR4 complex) (TLR4/MD-2/CD14)

The Toll-like receptor 4 (TLR4) complex, often referred to in the context of its interaction with Lipopolysaccharide (LPS), is a critical component of the innate immune system responsible for detecting Gram-negative bacterial pathogens (Park et al., 2009; PMID: 19363470). The functional signaling unit is a multimeric assembly consisting of the primary signaling receptor TLR4, the accessory protein MD-2 (Lymphocyte antigen 96), and the co-receptor CD14, which facilitates the transfer of LPS to the TLR4/MD-2 heterodimer (Lu et al., 2008; PMID: 18329281). Upon binding LPS—a potent endotoxin from the bacterial outer membrane—the complex undergoes a conformational change and dimerization, initiating intracellular signaling through MyD88 and TRIF adapter proteins. This process culminates in the activation of transcription factors like NF-κB and IRF3, leading to the robust production of pro-inflammatory cytokines and type I interferons (Kuzmich et al., 2017; PMID: 28243239). While essential for host defense, dysregulated or excessive activation of the TLR4 complex is a central driver in the pathogenesis of sepsis, septic shock, and various chronic inflammatory diseases (Ciesielska et al., 2021; PMID: 33146765). Consequently, the complex has been a major focus for drug development, with therapeutic strategies including TLR4 antagonists like Eritoran and small-molecule inhibitors like Resatorvid designed to mitigate systemic inflammation. However, clinical success has been limited by the complexity of the immune response and the potential for increased susceptibility to secondary infections when the pathway is inhibited (Monnet et al., 2020; PMID: 32459541).

Other names

LPS receptor complexCD14-TLR4-MD2 complexLipopolysaccharide receptorTLR4-MD2 complexToll-like receptor 4 signaling complex

Antagonism of the TLR4/MD-2 complex or neutralization of the LPS ligand to inhibit downstream pro-inflammatory signaling pathways.